{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:36:59Z","timestamp":1760315819665,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.eplepsyres.2003.12.001","type":"journal-article","created":{"date-parts":[[2004,2,10]],"date-time":"2004-02-10T05:17:53Z","timestamp":1076390273000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites"],"prefix":"10.1016","volume":"58","author":[{"given":"Nina","family":"Isoherranen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 H","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Yagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 H","family":"Woodhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Steve","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1023\/A:1016055517724","article-title":"Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide","volume":"13","author":"Bialer","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0928-0987(97)00081-X","article-title":"Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats","volume":"6","author":"Blotnik","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB4","unstructured":"Bourgeois, B.F.D., 2002. Valproic acid: efficacy and use in epilepsy. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E., (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 808\u2013827."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(25)12826-7","article-title":"Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes","volume":"277","author":"Bourrie","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB6","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB7","first-page":"303","article-title":"The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism","volume":"2","author":"Estabrook","year":"1972","journal-title":"Methods Pharmacol."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB8","unstructured":"Finney, D.J., 1971. Probit Analysis, 3rd ed. Cambridge University Press, Cambridge, UK."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB9","unstructured":"Genton, P.P., Gelisse, P., 2002. Valproic acid: adverse effects. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E. (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 837\u2013851."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB10","first-page":"207","article-title":"Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities","volume":"26","author":"Hickman","year":"1998","journal-title":"Drug Metab. Disposit."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1528-1157.2002.25801.x","article-title":"Anticonvulsant profile and teratogenicity of N-methyltetramethylcyclopropane carboxamide: a new antiepileptic drug","volume":"42","author":"Isoherranen","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00019052-200304000-00014","article-title":"New CNS-active drugs which are second generation valproic acid: can they lead to the development of a magic bullet?","volume":"16","author":"Isoherranen","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-1211(98)00084-9","article-title":"Congenital malformations due to antiepileptic drugs","volume":"33","author":"Kaneko","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-9556(25)07368-4","article-title":"Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependant metabolism of warfarin by fluconazole: in vitro studies","volume":"24","author":"Kunze","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(94)91050-2","article-title":"Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapid developing transient kindling and a slowly developing enduring kindling","volume":"649","author":"Lothman","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of inter- and intra-intestinal differences in human CYP3A-dependant metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/tx00018a012","article-title":"Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1","volume":"3","author":"Peter","year":"1990","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/0006-2952(83)90124-7","article-title":"The formation and metabolism of N-hydroxymethyl compounds-III. The metabolic conversion of N-methyl and N,N-dimethylbenzamides to N-hydroxymethyl-compounds","volume":"32","author":"Ross","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0378-4347(93)80302-K","article-title":"Simultaneous determination of N,N-dimethylformamide, N-monomethylformamide and N-hydroxymethyl-N-methylformamide in rat plasma by capillary gas chromatography","volume":"615","author":"Rosseel","year":"1993","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation\u2014a revisit with decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0090-9556(25)06814-X","article-title":"Metabolites of N-ethylbenzamide, N,N-diethylbenzamide and related compounds detected in rat urine by NMR spectroscopy","volume":"23","author":"Taylor","year":"1995","journal-title":"Drug Metab. Dipos."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0006-8993(99)02354-9","article-title":"Cytochrome P-450 activities in human and rat brain microsomes","volume":"855","author":"Voirol","year":"2000","journal-title":"Brain. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2003.12.001_BIB25","first-page":"S9","article-title":"Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs","volume":"38","author":"White","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB26","unstructured":"White, H.S., Woodhead, J.H., Wilcox, K.S., Stables, J.P., Kupferberg, H.J., Wolf, H.H., 2002. General principles: discovery and preclinical development of antiepileptic drugs. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca E. (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 36\u201348."},{"key":"10.1016\/j.eplepsyres.2003.12.001_BIB27","first-page":"897","article-title":"Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro","volume":"26","author":"Zhang","year":"2001","journal-title":"Drug Metab. Dispos."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121103002444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121103002444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:13:46Z","timestamp":1760274826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121103002444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0920121103002444"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2003.12.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2003.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}